首页 > 最新文献

Thyroid Research最新文献

英文 中文
Effectiveness of diffusion-weighted magnetic resonance imaging (DW-MRI) in the differentiation of thyroid nodules. 弥散加权磁共振成像(DW-MRI)在甲状腺结节分化中的有效性。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-11-18 DOI: 10.1186/s13044-024-00210-x
Bilgen Mehpare Özer, Yüksel Pabuşçu, Serdar Tarhan, Gülgün Yılmaz Ovalı, Hasan Aydede, Peyker Demireli, Tuğba Karadeniz

Background: The aim was to investigate which of two different b values (b 500 s/mm² and b 800 s/mm²) are more effective in the differentiation of benign-malignant nodules using Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI).

Materials and methods: Patients presenting with a preoperative diagnosis of nodular goiter or multinodular goiter were included in this study. These patients underwent neck MRI examinations, and their cases were analyzed retrospectively. A total of 26 patients were included in the study. A total of 46 nodules meeting the study criteria were examined. Measurements were performed on Apparent Diffusion Coefficient (ADC) maps of patients at two different b values (b 500 s/mm² and b 800 s/mm²), and the results were compared with histopathological findings.

Results: Out of a total of 46 nodules, 37 were identified as benign, and 9 as malignant based on histopathological analysis. The mean ADC value at b 500 was lower in malignant nodules (1259.65 ± 328.13) compared to benign nodules (19037.48 ± 472.74). Similarly, the mean ADC value at b 800 was lower in malignant nodules (1081.72 ± 200.23) compared to benign nodules (1610.44 ± 418.06). When a cut-off value of 1.1 × 10- 3 was accepted for the differentiation of pathology, the sensitivity for distinguishing pathology with ADC values at b 500 was 83.3%, with a specificity of 90.0%, and for ADC values at b 800, the sensitivity was 71.4%, with a specificity of 89.7%.

Conclusion: DW-MRI without the need for contrast agent administration is a useful method in the differentiation of benign-malignant thyroid nodules.

背景:目的是研究两种不同的b值(b 500 s/mm²和b 800 s/mm²)在使用弥散加权磁共振成像(DW-MRI)区分良恶性结节时哪个更有效:研究对象包括术前诊断为结节性甲状腺肿或多结节性甲状腺肿的患者。这些患者接受了颈部核磁共振成像检查,并对其病例进行了回顾性分析。研究共纳入了 26 名患者。共检查了 46 个符合研究标准的结节。在两种不同的b值(b 500 s/mm²和b 800 s/mm²)下对患者的表观扩散系数(ADC)图进行测量,并将结果与组织病理学结果进行比较:在总共 46 个结节中,根据组织病理学分析,37 个被确定为良性,9 个为恶性。恶性结节在 b 500 处的平均 ADC 值(1259.65 ± 328.13)低于良性结节(19037.48 ± 472.74)。同样,与良性结节(1610.44 ± 418.06)相比,恶性结节在 b 800 时的平均 ADC 值(1081.72 ± 200.23)也较低。如果以 1.1 × 10- 3 作为区分病理的临界值,则 b 500 ADC 值区分病理的灵敏度为 83.3%,特异度为 90.0%;b 800 ADC 值的灵敏度为 71.4%,特异度为 89.7%:结论:无需使用造影剂的 DW-MRI 是区分甲状腺结节良恶性的有效方法。
{"title":"Effectiveness of diffusion-weighted magnetic resonance imaging (DW-MRI) in the differentiation of thyroid nodules.","authors":"Bilgen Mehpare Özer, Yüksel Pabuşçu, Serdar Tarhan, Gülgün Yılmaz Ovalı, Hasan Aydede, Peyker Demireli, Tuğba Karadeniz","doi":"10.1186/s13044-024-00210-x","DOIUrl":"10.1186/s13044-024-00210-x","url":null,"abstract":"<p><strong>Background: </strong>The aim was to investigate which of two different b values (b 500 s/mm² and b 800 s/mm²) are more effective in the differentiation of benign-malignant nodules using Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI).</p><p><strong>Materials and methods: </strong>Patients presenting with a preoperative diagnosis of nodular goiter or multinodular goiter were included in this study. These patients underwent neck MRI examinations, and their cases were analyzed retrospectively. A total of 26 patients were included in the study. A total of 46 nodules meeting the study criteria were examined. Measurements were performed on Apparent Diffusion Coefficient (ADC) maps of patients at two different b values (b 500 s/mm² and b 800 s/mm²), and the results were compared with histopathological findings.</p><p><strong>Results: </strong>Out of a total of 46 nodules, 37 were identified as benign, and 9 as malignant based on histopathological analysis. The mean ADC value at b 500 was lower in malignant nodules (1259.65 ± 328.13) compared to benign nodules (19037.48 ± 472.74). Similarly, the mean ADC value at b 800 was lower in malignant nodules (1081.72 ± 200.23) compared to benign nodules (1610.44 ± 418.06). When a cut-off value of 1.1 × 10<sup>- 3</sup> was accepted for the differentiation of pathology, the sensitivity for distinguishing pathology with ADC values at b 500 was 83.3%, with a specificity of 90.0%, and for ADC values at b 800, the sensitivity was 71.4%, with a specificity of 89.7%.</p><p><strong>Conclusion: </strong>DW-MRI without the need for contrast agent administration is a useful method in the differentiation of benign-malignant thyroid nodules.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"17 1","pages":"24"},"PeriodicalIF":1.9,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Losartan is more effective than angiotensin (1-7) in preventing thyroxine-induced renal injury in the rat. 在预防甲状腺素诱发的大鼠肾损伤方面,洛沙坦比血管紧张素(1-7)更有效。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-11-04 DOI: 10.1186/s13044-024-00211-w
Slava Malatiali, Mabayoje Oriowo

Aim: Studies have shown that renal hypertrophy seen in experimental hyperthyroidism induced by thyroxine (T4) is due to angiotensin (Ang) II. However, other renal effects of Ang II in experimental hyperthyroidism have not been investigated. In addition, Ang 1-7 is believed to be protective against renal injury, but its possible role in thyroxine-induced renal injury is not known. The aim of this study is to elaborate the role of Ang II in thyroxine-induced renal injury and the possible protective role of Ang 1-7. We hypothesize that Ang 1-7 will be as protective against thyroxine-induced renal injury as the use of an ACE inhibitor or an Ang II receptor blocker.

Methods: Adult Sprague Dawley rats were used in this study and were divided into 5 groups: (1) Control (treated with vehicle), (2) Treated with thyroxine (T4, 100 µg/kg), (3) Treated with T4 and Ang 1-7 (500 µg/kg), (4) Treated with T4 and captopril (20 mg/kg), and (5) Treated with T4 and losartan (10 mg/kg). Parameters tested after fourteen days of treatment were creatinine clearance, protein excretion rate, glomerular volume, renal ACE1 and ACE2 protein expression. Data were compared using One-way-ANOVA followed by Tukey's HSD post hoc test.

Results: Thyroxine caused glomerular hypertrophy and proteinuria but had no effect on glomerular filtration rate (GFR). Glomerular hypertrophy was prevented by losartan and captopril, but not by Ang 1-7. Captopril and losartan had no effect on GFR; however, Ang 1-7 caused an increase in GFR in T4-treated rats. The increase in protein excretion rate was prevented by losartan but not by captopril or Ang 1-7. Renal expression of ACE1 protein was not altered in any of the treatment groups except in captopril treated rats were ACE1 expression was increased. Renal ACE2 protein expression was only increased in T4-losartan-treated rats and not affected by any of the other treatments.

Conclusion: We conclude that losartan was more protective than captopril against thyroxine-induced renal changes while Ang 1-7 offered no protection.

目的:研究表明,甲状腺素(T4)诱导的实验性甲状腺机能亢进症的肾脏肥大是由血管紧张素(Ang)II引起的。然而,Ang II 对实验性甲状腺机能亢进症肾脏的其他影响尚未得到研究。此外,Ang 1-7 被认为对肾损伤具有保护作用,但其在甲状腺素诱导的肾损伤中可能发挥的作用尚不清楚。本研究旨在阐述 Ang II 在甲状腺素诱导的肾损伤中的作用以及 Ang 1-7 可能发挥的保护作用。我们假设 Ang 1-7 与使用 ACE 抑制剂或 Ang II 受体阻断剂一样,对甲状腺素诱导的肾损伤具有保护作用:本研究使用成年 Sprague Dawley 大鼠,并将其分为 5 组:(1) 对照组(使用药物治疗);(2) 使用甲状腺素(T4,100 µg/kg)治疗;(3) 使用 T4 和 Ang 1-7 (500 µg/kg)治疗;(4) 使用 T4 和卡托普利(20 mg/kg)治疗;(5) 使用 T4 和洛沙坦(10 mg/kg)治疗。治疗 14 天后检测的参数包括肌酐清除率、蛋白质排泄率、肾小球体积、肾脏 ACE1 和 ACE2 蛋白表达。数据比较采用单因素方差分析(One-way-ANOVA),然后进行Tukey's HSD事后检验:结果:甲状腺素会导致肾小球肥大和蛋白尿,但对肾小球滤过率(GFR)没有影响。洛沙坦和卡托普利能防止肾小球肥大,但 Ang 1-7 不能。卡托普利和洛沙坦对肾小球滤过率没有影响;但 Ang 1-7 可使 T4 治疗大鼠的肾小球滤过率增加。洛沙坦能阻止蛋白质排泄率的增加,而卡托普利或 Ang 1-7 则不能。除卡托普利治疗组大鼠的 ACE1 蛋白表达增加外,其他治疗组大鼠的肾脏 ACE1 蛋白表达均无变化。肾脏 ACE2 蛋白表达仅在 T4-洛沙坦处理的大鼠中增加,而不受其他任何处理的影响:我们得出结论:洛沙坦比卡托普利对甲状腺素诱导的肾脏变化更有保护作用,而 Ang 1-7 则没有保护作用。
{"title":"Losartan is more effective than angiotensin (1-7) in preventing thyroxine-induced renal injury in the rat.","authors":"Slava Malatiali, Mabayoje Oriowo","doi":"10.1186/s13044-024-00211-w","DOIUrl":"10.1186/s13044-024-00211-w","url":null,"abstract":"<p><strong>Aim: </strong>Studies have shown that renal hypertrophy seen in experimental hyperthyroidism induced by thyroxine (T4) is due to angiotensin (Ang) II. However, other renal effects of Ang II in experimental hyperthyroidism have not been investigated. In addition, Ang 1-7 is believed to be protective against renal injury, but its possible role in thyroxine-induced renal injury is not known. The aim of this study is to elaborate the role of Ang II in thyroxine-induced renal injury and the possible protective role of Ang 1-7. We hypothesize that Ang 1-7 will be as protective against thyroxine-induced renal injury as the use of an ACE inhibitor or an Ang II receptor blocker.</p><p><strong>Methods: </strong>Adult Sprague Dawley rats were used in this study and were divided into 5 groups: (1) Control (treated with vehicle), (2) Treated with thyroxine (T4, 100 µg/kg), (3) Treated with T4 and Ang 1-7 (500 µg/kg), (4) Treated with T4 and captopril (20 mg/kg), and (5) Treated with T4 and losartan (10 mg/kg). Parameters tested after fourteen days of treatment were creatinine clearance, protein excretion rate, glomerular volume, renal ACE1 and ACE2 protein expression. Data were compared using One-way-ANOVA followed by Tukey's HSD post hoc test.</p><p><strong>Results: </strong>Thyroxine caused glomerular hypertrophy and proteinuria but had no effect on glomerular filtration rate (GFR). Glomerular hypertrophy was prevented by losartan and captopril, but not by Ang 1-7. Captopril and losartan had no effect on GFR; however, Ang 1-7 caused an increase in GFR in T4-treated rats. The increase in protein excretion rate was prevented by losartan but not by captopril or Ang 1-7. Renal expression of ACE1 protein was not altered in any of the treatment groups except in captopril treated rats were ACE1 expression was increased. Renal ACE2 protein expression was only increased in T4-losartan-treated rats and not affected by any of the other treatments.</p><p><strong>Conclusion: </strong>We conclude that losartan was more protective than captopril against thyroxine-induced renal changes while Ang 1-7 offered no protection.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"17 1","pages":"22"},"PeriodicalIF":1.9,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The diagnostic performance of neck ultrasound in follow-up of advanced stage differentiated thyroid cancer. 颈部超声波在晚期分化型甲状腺癌随访中的诊断性能。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-14 DOI: 10.1186/s13044-024-00213-8
Vicki Munro, Syed Mustafa, Ferhan S Siddiqi, Murali Rajaraman, Andreu F Costa, Syed Ali Imran

Background: Differentiated thyroid cancer (DTC) requires long-term follow-up due to the risk of delayed recurrence. Follow-up surveillance involves serial neck ultrasound (US) and thyroglobulin (Tg); however, the optimal frequency and diagnostic performance of neck US outside of specialized thyroid cancer centres in higher risk patients is not well defined. We sought to evaluate the diagnostic performance of US and serial Tg in advanced stage DTC.

Methods: We retrospectively reviewed our thyroid cancer database for patients with stage III and IV DTC from 2006 to 2018, total thyroidectomy, and at least 2 years follow-up to assess recurrence rates. Those with hemi-thyroidectomy or anti-Tg antibodies were excluded. Diagnostic performance of US and Tg were assessed using a composite reference standard of follow-up imaging and pathology. All relevant US were reviewed by a blinded expert radiologist for uniformity.

Results: Of 136 included patients (91 females, mean age 58.9), 26 (19%) had recurrence of DTC over median follow-up of 6.6 years (IQR 5.3-9.3). The sensitivity and specificity of US in diagnosing cervical recurrence were 73.3% (95% CI 0.51-0.96) and 68.3% (95% CI 0.60-0.77) based on historical reports, respectively, and 80% (95% CI 0.60-1.00) and 87.8% (95% CI 0.82-0.93) based on blinded expert review, respectively. Tg had a sensitivity of 95.5% (95% CI 0.89-1.0) and specificity of 96.2% (95% CI 0.92-0.99) in detecting cervical recurrence or distant metastases. False positive US findings on historical US and subsequent review occurred in 38 (28%) and 15 (11%) patients, respectively, while 5 (3.6%) had false positive Tg results.

Conclusion: Serial Tg has better sensitivity and specificity than US for detecting recurrence of advanced stage DTC. Furthermore, re-interpretation of abnormal findings using structured US reporting with a subspecialized reader may improve diagnostic performance of US and improve its utility in clinical care.

背景:分化型甲状腺癌(DTC)有延迟复发的风险,因此需要长期随访。随访监测包括连续性颈部超声(US)和甲状腺球蛋白(Tg)检查;然而,在甲状腺癌专科中心以外,对高危患者进行颈部US检查的最佳频率和诊断效果尚无明确定义。我们试图评估颈部 US 和连续 Tg 对晚期 DTC 的诊断效果:我们回顾性地查看了甲状腺癌数据库中2006年至2018年期间III期和IV期DTC患者的资料,对其进行了甲状腺全切除术,并进行了至少2年的随访,以评估复发率。排除了半甲状腺切除术或抗Tg抗体患者。采用随访影像学和病理学的综合参考标准评估US和Tg的诊断性能。所有相关的 US 均由一名盲法放射学专家进行审查,以确保一致性:在纳入的136名患者(91名女性,平均年龄58.9岁)中,26人(19%)在中位随访6.6年(IQR 5.3-9.3)后DTC复发。根据历史报告,US 诊断宫颈复发的敏感性和特异性分别为 73.3% (95% CI 0.51-0.96) 和 68.3% (95% CI 0.60-0.77);根据盲法专家审查,US 诊断宫颈复发的敏感性和特异性分别为 80% (95% CI 0.60-1.00) 和 87.8% (95% CI 0.82-0.93)。在检测宫颈复发或远处转移方面,Tg 的灵敏度为 95.5%(95% CI 0.89-1.0),特异性为 96.2%(95% CI 0.92-0.99)。38名患者(28%)和15名患者(11%)分别在历史US检查和后续复查中发现假阳性US结果,而5名患者(3.6%)的Tg结果为假阳性:结论:在检测晚期 DTC 复发方面,连续 Tg 比 US 具有更好的敏感性和特异性。此外,使用结构化的 US 报告和亚专业阅读器重新解释异常结果可提高 US 的诊断性能并改善其在临床护理中的实用性。
{"title":"The diagnostic performance of neck ultrasound in follow-up of advanced stage differentiated thyroid cancer.","authors":"Vicki Munro, Syed Mustafa, Ferhan S Siddiqi, Murali Rajaraman, Andreu F Costa, Syed Ali Imran","doi":"10.1186/s13044-024-00213-8","DOIUrl":"https://doi.org/10.1186/s13044-024-00213-8","url":null,"abstract":"<p><strong>Background: </strong>Differentiated thyroid cancer (DTC) requires long-term follow-up due to the risk of delayed recurrence. Follow-up surveillance involves serial neck ultrasound (US) and thyroglobulin (Tg); however, the optimal frequency and diagnostic performance of neck US outside of specialized thyroid cancer centres in higher risk patients is not well defined. We sought to evaluate the diagnostic performance of US and serial Tg in advanced stage DTC.</p><p><strong>Methods: </strong>We retrospectively reviewed our thyroid cancer database for patients with stage III and IV DTC from 2006 to 2018, total thyroidectomy, and at least 2 years follow-up to assess recurrence rates. Those with hemi-thyroidectomy or anti-Tg antibodies were excluded. Diagnostic performance of US and Tg were assessed using a composite reference standard of follow-up imaging and pathology. All relevant US were reviewed by a blinded expert radiologist for uniformity.</p><p><strong>Results: </strong>Of 136 included patients (91 females, mean age 58.9), 26 (19%) had recurrence of DTC over median follow-up of 6.6 years (IQR 5.3-9.3). The sensitivity and specificity of US in diagnosing cervical recurrence were 73.3% (95% CI 0.51-0.96) and 68.3% (95% CI 0.60-0.77) based on historical reports, respectively, and 80% (95% CI 0.60-1.00) and 87.8% (95% CI 0.82-0.93) based on blinded expert review, respectively. Tg had a sensitivity of 95.5% (95% CI 0.89-1.0) and specificity of 96.2% (95% CI 0.92-0.99) in detecting cervical recurrence or distant metastases. False positive US findings on historical US and subsequent review occurred in 38 (28%) and 15 (11%) patients, respectively, while 5 (3.6%) had false positive Tg results.</p><p><strong>Conclusion: </strong>Serial Tg has better sensitivity and specificity than US for detecting recurrence of advanced stage DTC. Furthermore, re-interpretation of abnormal findings using structured US reporting with a subspecialized reader may improve diagnostic performance of US and improve its utility in clinical care.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"17 1","pages":"23"},"PeriodicalIF":1.9,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142476953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sonographic characteristics of thyroid nodules with a Halo. 带有光环的甲状腺结节的声像图特征。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-01 DOI: 10.1186/s13044-024-00208-5
Danming Cao, Rong Zou, Ming Zhang, Kui Tang

Objective: To investigate the sonographic characteristics of thyroid nodules with a halo, explore the value of contrast-enhanced ultrasound (CEUS) combined with fine needle aspiration (FNA) in identifying nodules with a halo, and predict the risk of metastasis by analyzing the pathological features of the halo.

Methods: A retrospective analysis was conducted on 185 postoperative cases of thyroid nodules accompanied by halos between January 2019 and December 2022. After describing the ultrasound characteristics of the thyroid nodules and their halos, all patients were divided into three groups, the first group (group I = CEUS only) of patients underwent CEUS, the second group (group II = CEUS + FNA) underwent FNA based on the first group, and the third group (group III = FNA only) underwent FNA directly. The CEUS and FNA results were graded using the Chinese Thyroid Imaging Report and Data System (C-TIRADS) and Bethesda Reporting System for Thyroid Cytopathology, respectively. Those graded below C-TIRADS 4b or Bethesda IV were defined as benign, and the results of FNA were referenced when the two methods were combined. The surgical pathology results were used as the gold standard. We plotted working curves to compare the diagnostic efficacy of CEUS and FNA alone and in combination in the diagnosis of thyroid nodules with halos. The pathological features of the halo were analyzed and the number of patients with cervical lymph node metastases was recorded.

Results: One hundred and sixty patients met the requirements. Benign nodules were mainly characterized by a thin (0.75 ± 0.31 mm) and uniform halo with good integrity, while malignant nodules had a thicker (1.48 ± 0.51 mm) halo with uneven and irregular margins (P < 0.05). The sensitivity and specificity were highest when the cutoff value was 1.09 mm, with 76.08% and 84.29%, respectively. The halos of benign nodules were mostly hyper- or iso-enhanced, whereas the halos of malignant nodules were predominantly hypo-enhanced (P < 0.05). The areas under the curve (AUCs) for CEUS, FNA, and CEUS + FNA were 0.751(95% CI = 0.642-0.841), 0.863(95% CI = 0.767-0.929), and 0.918(95% CI = 0.834-0.967), respectively. Cervical lymph node metastasis occurred in only 13 (11.5%) malignant nodes with halos. The primary pathological components of the halo around malignant nodules were almost reactive hyperplastic fibrous tissue.

Conclusion: The halo surrounding malignant thyroid nodules is thicker, with uneven and irregular margins, and shows hypo-enhancement on CEUS. Combining CEUS with FNA improves the diagnostic efficacy of thyroid nodules with halos. The reactive hyperplastic fibrous halo may be one of the reasons why malignant nodules are less likely to metastasize.

目的研究甲状腺结节伴晕的声像图特征,探讨造影剂增强超声(CEUS)联合细针穿刺(FNA)在识别甲状腺结节伴晕中的价值,并通过分析晕的病理特征预测转移风险:方法:对2019年1月至2022年12月期间185例甲状腺结节术后伴有光环的病例进行回顾性分析。在描述甲状腺结节及其光晕的超声特征后,将所有患者分为三组,第一组(Ⅰ组=仅CEUS)患者进行CEUS检查,第二组(Ⅱ组=CEUS+FNA)在第一组的基础上进行FNA检查,第三组(Ⅲ组=仅FNA)直接进行FNA检查。CEUS和FNA结果分别采用中国甲状腺影像报告和数据系统(C-TIRADS)和贝塞斯达甲状腺细胞病理学报告系统进行分级。分级低于 C-TIRADS 4b 或 Bethesda IV 级者定义为良性,两种方法合并时参考 FNA 的结果。手术病理结果作为金标准。我们绘制了工作曲线,以比较 CEUS 和 FNA 单独或联合诊断甲状腺结节光环的疗效。我们分析了光环的病理特征,并记录了有颈淋巴结转移的患者人数:结果:160 名患者符合要求。良性结节的主要特征是光环较薄(0.75±0.31 毫米)且均匀一致,完整性良好,而恶性结节的光环较厚(1.48±0.51 毫米),边缘不均匀且不规则(P 结论:良性结节的光环较薄,边缘不均匀且不规则,而恶性结节的光环较厚(1.48±0.51 毫米),边缘不均匀且不规则:恶性甲状腺结节周围的光环较厚,边缘不均匀且不规则,在CEUS上显示低增强。将 CEUS 与 FNA 结合使用可提高甲状腺结节光环的诊断效果。反应性增生纤维晕可能是恶性结节不易转移的原因之一。
{"title":"Sonographic characteristics of thyroid nodules with a Halo.","authors":"Danming Cao, Rong Zou, Ming Zhang, Kui Tang","doi":"10.1186/s13044-024-00208-5","DOIUrl":"10.1186/s13044-024-00208-5","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the sonographic characteristics of thyroid nodules with a halo, explore the value of contrast-enhanced ultrasound (CEUS) combined with fine needle aspiration (FNA) in identifying nodules with a halo, and predict the risk of metastasis by analyzing the pathological features of the halo.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 185 postoperative cases of thyroid nodules accompanied by halos between January 2019 and December 2022. After describing the ultrasound characteristics of the thyroid nodules and their halos, all patients were divided into three groups, the first group (group I = CEUS only) of patients underwent CEUS, the second group (group II = CEUS + FNA) underwent FNA based on the first group, and the third group (group III = FNA only) underwent FNA directly. The CEUS and FNA results were graded using the Chinese Thyroid Imaging Report and Data System (C-TIRADS) and Bethesda Reporting System for Thyroid Cytopathology, respectively. Those graded below C-TIRADS 4b or Bethesda IV were defined as benign, and the results of FNA were referenced when the two methods were combined. The surgical pathology results were used as the gold standard. We plotted working curves to compare the diagnostic efficacy of CEUS and FNA alone and in combination in the diagnosis of thyroid nodules with halos. The pathological features of the halo were analyzed and the number of patients with cervical lymph node metastases was recorded.</p><p><strong>Results: </strong>One hundred and sixty patients met the requirements. Benign nodules were mainly characterized by a thin (0.75 ± 0.31 mm) and uniform halo with good integrity, while malignant nodules had a thicker (1.48 ± 0.51 mm) halo with uneven and irregular margins (P < 0.05). The sensitivity and specificity were highest when the cutoff value was 1.09 mm, with 76.08% and 84.29%, respectively. The halos of benign nodules were mostly hyper- or iso-enhanced, whereas the halos of malignant nodules were predominantly hypo-enhanced (P < 0.05). The areas under the curve (AUCs) for CEUS, FNA, and CEUS + FNA were 0.751(95% CI = 0.642-0.841), 0.863(95% CI = 0.767-0.929), and 0.918(95% CI = 0.834-0.967), respectively. Cervical lymph node metastasis occurred in only 13 (11.5%) malignant nodes with halos. The primary pathological components of the halo around malignant nodules were almost reactive hyperplastic fibrous tissue.</p><p><strong>Conclusion: </strong>The halo surrounding malignant thyroid nodules is thicker, with uneven and irregular margins, and shows hypo-enhancement on CEUS. Combining CEUS with FNA improves the diagnostic efficacy of thyroid nodules with halos. The reactive hyperplastic fibrous halo may be one of the reasons why malignant nodules are less likely to metastasize.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"17 1","pages":"20"},"PeriodicalIF":1.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation between gene mutations and clinical characteristics in papillary thyroid cancer: a retrospective analysis of BRAF mutations and RET rearrangements. 甲状腺乳头状癌基因突变与临床特征之间的相关性:对BRAF突变和RET重排的回顾性分析。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-09-16 DOI: 10.1186/s13044-024-00209-4
Daisuke Uno, Kazuhira Endo, Tomomi Yoshikawa, Nobuyuki Hirai, Eiji Kobayashi, Yosuke Nakanishi, Satoru Kondo, Tomokazu Yoshizaki

Introduction: Activation of the MAPK pathway by genetic mutations (such as BRAF and RET) initiates and accelerates the growth of papillary thyroid carcinoma (PTC). However, the correlation between genetic mutations and clinical features remains to be established. Therefore, this study aimed to retrospectively analyze major genetic mutations, specifically BRAF mutations and RET rearrangements, and develop a treatment algorithm by comparing background and clinical characteristics.

Method: One hundred thirteen patients with primary PTC were included in this study. BRAF mutations were detected via Sanger sequencing and RET rearrangements were detected via fluorescence in situ hybridization (FISH) analysis, and reverse transcription polymerase chain reaction (RT-PCR). The patients were categorized into two groups based on the presence of BRAF mutations and RET rearrangements and their clinical characteristics (age, sex, TNM, stage, extratumoral extension, tumor size, unifocal/multifocal lesions, vascular invasion, differentiation, chronic thyroiditis, preoperative serum thyroglobulin level, and 18F-fluorodeoxyglucose (FDG) uptake) were compared subsequently.

Result: After excluding unanalyzable specimens, 80 PTC patients (22 males and 58 females, mean age: 57.2 years) were included in the study. RET rearrangements were positive in 8 cases (10%), and BRAF mutation was positive in 63 (78.6%). The RET rearrangement group was significantly associated with younger age (p = 0.024), multifocal lesion (p = 0.048), distant metastasis (p = 0.025) and decreased 18F-fluorodeoxyglucose uptake (p < 0.001). The BRAF mutation group was significantly associated with unifocal lesions (p = 0.02) and increased 18F-FDG uptake (p = 0.004).

Conclusion: In this study, an increase in M classification cases was found in the RET rearrangements group. However, genetic mutations were not associated with the clinical stage, and no factors that could be incorporated into the treatment algorithm were identified.

简介基因突变(如 BRAF 和 RET)激活了 MAPK 通路,启动并加速了甲状腺乳头状癌(PTC)的生长。然而,基因突变与临床特征之间的相关性仍有待确定。因此,本研究旨在回顾性分析主要基因突变,特别是BRAF突变和RET重排,并通过比较背景和临床特征制定治疗算法:本研究共纳入 113 例原发性 PTC 患者。通过桑格测序检测 BRAF 突变,通过荧光原位杂交(FISH)分析和反转录聚合酶链反应(RT-PCR)检测 RET 重排。根据 BRAF 基因突变和 RET 基因重排情况将患者分为两组,并比较两组患者的临床特征(年龄、性别、TNM、分期、瘤外扩展、肿瘤大小、单灶/多灶病变、血管侵犯、分化、慢性甲状腺炎、术前血清甲状腺球蛋白水平和 18F- 氟脱氧葡萄糖(FDG)摄取量):在排除了无法分析的标本后,80 例 PTC 患者(男 22 例,女 58 例,平均年龄 57.2 岁)被纳入研究范围。8例(10%)RET重排阳性,63例(78.6%)BRAF突变阳性。RET重排组与年轻(p = 0.024)、多灶性病变(p = 0.048)、远处转移(p = 0.025)和18F-氟脱氧葡萄糖摄取减少(p 18F-FDG uptake (p = 0.004))显著相关:本研究发现,RET重排组的M分类病例有所增加。然而,基因突变与临床分期无关,也未发现可纳入治疗算法的因素。
{"title":"Correlation between gene mutations and clinical characteristics in papillary thyroid cancer: a retrospective analysis of BRAF mutations and RET rearrangements.","authors":"Daisuke Uno, Kazuhira Endo, Tomomi Yoshikawa, Nobuyuki Hirai, Eiji Kobayashi, Yosuke Nakanishi, Satoru Kondo, Tomokazu Yoshizaki","doi":"10.1186/s13044-024-00209-4","DOIUrl":"https://doi.org/10.1186/s13044-024-00209-4","url":null,"abstract":"<p><strong>Introduction: </strong>Activation of the MAPK pathway by genetic mutations (such as BRAF and RET) initiates and accelerates the growth of papillary thyroid carcinoma (PTC). However, the correlation between genetic mutations and clinical features remains to be established. Therefore, this study aimed to retrospectively analyze major genetic mutations, specifically BRAF mutations and RET rearrangements, and develop a treatment algorithm by comparing background and clinical characteristics.</p><p><strong>Method: </strong>One hundred thirteen patients with primary PTC were included in this study. BRAF mutations were detected via Sanger sequencing and RET rearrangements were detected via fluorescence in situ hybridization (FISH) analysis, and reverse transcription polymerase chain reaction (RT-PCR). The patients were categorized into two groups based on the presence of BRAF mutations and RET rearrangements and their clinical characteristics (age, sex, TNM, stage, extratumoral extension, tumor size, unifocal/multifocal lesions, vascular invasion, differentiation, chronic thyroiditis, preoperative serum thyroglobulin level, and <sup>18</sup>F-fluorodeoxyglucose (FDG) uptake) were compared subsequently.</p><p><strong>Result: </strong>After excluding unanalyzable specimens, 80 PTC patients (22 males and 58 females, mean age: 57.2 years) were included in the study. RET rearrangements were positive in 8 cases (10%), and BRAF mutation was positive in 63 (78.6%). The RET rearrangement group was significantly associated with younger age (p = 0.024), multifocal lesion (p = 0.048), distant metastasis (p = 0.025) and decreased <sup>18</sup>F-fluorodeoxyglucose uptake (p < 0.001). The BRAF mutation group was significantly associated with unifocal lesions (p = 0.02) and increased <sup>18</sup>F-FDG uptake (p = 0.004).</p><p><strong>Conclusion: </strong>In this study, an increase in M classification cases was found in the RET rearrangements group. However, genetic mutations were not associated with the clinical stage, and no factors that could be incorporated into the treatment algorithm were identified.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"17 1","pages":"21"},"PeriodicalIF":1.9,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of LINC02454-related key pathways and genes in papillary thyroid cancer by weighted gene coexpression network analysis (WGCNA). 通过加权基因共表达网络分析(WGCNA)鉴定甲状腺乳头状癌中与LINC02454相关的关键通路和基因
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-09-02 DOI: 10.1186/s13044-024-00205-8
Yingjian Song, Lin Wang, Yi Ren, Xilei Zhou, Juan Tan

Background: Our previous study demonstrated that long intergenic noncoding RNA 02454 (LINC02454) may act as an oncogene to promote the proliferation and inhibit the apoptosis of papillary thyroid cancer (PTC) cells. This study was designed to investigate the mechanisms whereby LINC02454 is related to PTC tumorigenesis.

Methods: Thyroid cancer RNA sequence data were obtained from The Cancer Genome Atlas (TCGA) database. Weighted gene coexpression network analysis (WGCNA) was applied to identify modules closely associated with PTC. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was used to identify the key pathways, and the maximal clique centrality (MCC) topological method was used to identify the hub genes. The Gene Expression Profiling Interactive Analysis (GEPIA) database was used to compare expression levels of key genes between PTC samples and normal samples and explore the prognostic value of key genes. The key genes were further validated with GEO dataset.

Results: The top 5000 variable genes were investigated, followed by an analysis of 8 modules, and the turquoise module was the most positively correlated with the clinical stage of PTC. KEGG pathway analysis found the top two pathways of the ECM - receptor interaction and MAPK signaling pathway. In addition, five key genes (FN1, LAMB3, ITGA3, SDC4, and IL1RAP) were identified through the MCC algorithm and KEGG analysis. The expression levels of the five key genes were significantly upregulated in thyroid cancer in both TCGA and GEO datasets, and of these five genes, FN1 and ITGA3 were associated with poor disease-free prognosis.

Conclusions: Our study identified five key genes and two key pathways associated with LINC02454, which might shed light on the underlying mechanism of LINC02454 action in PTC.

背景:我们之前的研究表明,长基因间非编码RNA 02454(LINC02454)可能作为一种癌基因促进甲状腺乳头状癌(PTC)细胞的增殖并抑制其凋亡。本研究旨在探讨LINC02454与PTC肿瘤发生的相关机制:甲状腺癌 RNA 序列数据来自癌症基因组图谱(TCGA)数据库。应用加权基因共表达网络分析(WGCNA)确定与 PTC 密切相关的模块。利用京都基因组百科全书(KEGG)通路富集分析确定关键通路,并利用最大克隆中心性(MCC)拓扑方法确定枢纽基因。基因表达谱交互分析(GEPIA)数据库用于比较PTC样本和正常样本中关键基因的表达水平,并探索关键基因的预后价值。结果发现,前 5000 个可变基因的表达水平均高于正常样本:对前 5000 个可变基因进行了调查,然后对 8 个模块进行了分析,其中绿松石模块与 PTC 临床分期的正相关性最高。KEGG通路分析发现,ECM-受体相互作用通路和MAPK信号通路位居前两位。此外,通过 MCC 算法和 KEGG 分析还发现了五个关键基因(FN1、LAMB3、ITGA3、SDC4 和 IL1RAP)。在TCGA和GEO数据集中,这五个关键基因在甲状腺癌中的表达水平均显著上调,其中FN1和ITGA3与无病预后不良有关:我们的研究发现了与LINC02454相关的5个关键基因和2个关键通路,这可能揭示了LINC02454在PTC中发挥作用的潜在机制。
{"title":"Identification of LINC02454-related key pathways and genes in papillary thyroid cancer by weighted gene coexpression network analysis (WGCNA).","authors":"Yingjian Song, Lin Wang, Yi Ren, Xilei Zhou, Juan Tan","doi":"10.1186/s13044-024-00205-8","DOIUrl":"10.1186/s13044-024-00205-8","url":null,"abstract":"<p><strong>Background: </strong>Our previous study demonstrated that long intergenic noncoding RNA 02454 (LINC02454) may act as an oncogene to promote the proliferation and inhibit the apoptosis of papillary thyroid cancer (PTC) cells. This study was designed to investigate the mechanisms whereby LINC02454 is related to PTC tumorigenesis.</p><p><strong>Methods: </strong>Thyroid cancer RNA sequence data were obtained from The Cancer Genome Atlas (TCGA) database. Weighted gene coexpression network analysis (WGCNA) was applied to identify modules closely associated with PTC. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was used to identify the key pathways, and the maximal clique centrality (MCC) topological method was used to identify the hub genes. The Gene Expression Profiling Interactive Analysis (GEPIA) database was used to compare expression levels of key genes between PTC samples and normal samples and explore the prognostic value of key genes. The key genes were further validated with GEO dataset.</p><p><strong>Results: </strong>The top 5000 variable genes were investigated, followed by an analysis of 8 modules, and the turquoise module was the most positively correlated with the clinical stage of PTC. KEGG pathway analysis found the top two pathways of the ECM - receptor interaction and MAPK signaling pathway. In addition, five key genes (FN1, LAMB3, ITGA3, SDC4, and IL1RAP) were identified through the MCC algorithm and KEGG analysis. The expression levels of the five key genes were significantly upregulated in thyroid cancer in both TCGA and GEO datasets, and of these five genes, FN1 and ITGA3 were associated with poor disease-free prognosis.</p><p><strong>Conclusions: </strong>Our study identified five key genes and two key pathways associated with LINC02454, which might shed light on the underlying mechanism of LINC02454 action in PTC.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"17 1","pages":"17"},"PeriodicalIF":1.9,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artemisinin ameliorates thyroid function and complications in adult male hypothyroid rats via upregulation of the L1 cell adhesion molecule. 青蒿素通过上调 L1 细胞粘附分子改善成年雄性甲状腺功能减退大鼠的甲状腺功能和并发症。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-19 DOI: 10.1186/s13044-024-00206-7
Lingling Li, Haifan Xu, Zecheng Hu, Li Li

Background: Hypothyroidism, a common worldwide syndrome caused by insufficient thyroid hormone secretion, affects number of people at different ages. Artemisinin (ART), a well-known effective agent in the treatment of malaria, also has anti-oxidative stress functions in various diseases. The L1 cell adhesion molecule exerts multiple protective roles in diseased systems. The aim of the present study was to evaluate the role of ART in adult male hypothyroid rats and the underlying mechanisms.

Methods: The propylthiouracil (PTU) rat model was treated with or without 5 mg/kg ART and with or without L1 short-interfering RNA (siRNA), followed by the experiments to determine the effect of ART on thyroid function, depression and anxiety, cognition impairments, liver, kidney and heart functions, and oxidative stress.

Results: In the current study, it was shown that ART can ameliorate thyroid function, mitigate depression and anxiety symptoms, attenuate cognition impairments, improve liver, kidney and heart functions, and inhibit oxidative stress; however, the effects exerted by ART could not be observed when L1 was silenced by L1 siRNA.

Conclusion: These results indicated that ART can upregulate the L1 cell adhesion molecule to ameliorate thyroid function and the complications in adult male hypothyroid rats, laying the foundation for ART to be a novel strategy for the treatment of hypothyroidism.

背景:甲状腺功能减退症是由甲状腺激素分泌不足引起的一种常见的世界性综合征,影响着不同年龄段的人群。青蒿素(ART)是众所周知的治疗疟疾的有效药物,在多种疾病中也具有抗氧化应激功能。L1 细胞粘附分子在疾病系统中发挥着多重保护作用。本研究旨在评估 ART 对成年雄性甲状腺功能减退大鼠的作用及其内在机制:丙基硫脲嘧啶(PTU)大鼠模型接受或不接受 5 mg/kg ART 和 L1 短干扰 RNA(siRNA)治疗,然后通过实验确定 ART 对甲状腺功能、抑郁和焦虑、认知障碍、肝脏、肾脏和心脏功能以及氧化应激的影响:本研究表明,ART能改善甲状腺功能,缓解抑郁和焦虑症状,减轻认知障碍,改善肝、肾和心脏功能,抑制氧化应激:这些结果表明,ART能上调L1细胞粘附分子,从而改善成年雄性甲减大鼠的甲状腺功能和并发症,为ART成为治疗甲减的一种新策略奠定了基础。
{"title":"Artemisinin ameliorates thyroid function and complications in adult male hypothyroid rats via upregulation of the L1 cell adhesion molecule.","authors":"Lingling Li, Haifan Xu, Zecheng Hu, Li Li","doi":"10.1186/s13044-024-00206-7","DOIUrl":"10.1186/s13044-024-00206-7","url":null,"abstract":"<p><strong>Background: </strong>Hypothyroidism, a common worldwide syndrome caused by insufficient thyroid hormone secretion, affects number of people at different ages. Artemisinin (ART), a well-known effective agent in the treatment of malaria, also has anti-oxidative stress functions in various diseases. The L1 cell adhesion molecule exerts multiple protective roles in diseased systems. The aim of the present study was to evaluate the role of ART in adult male hypothyroid rats and the underlying mechanisms.</p><p><strong>Methods: </strong>The propylthiouracil (PTU) rat model was treated with or without 5 mg/kg ART and with or without L1 short-interfering RNA (siRNA), followed by the experiments to determine the effect of ART on thyroid function, depression and anxiety, cognition impairments, liver, kidney and heart functions, and oxidative stress.</p><p><strong>Results: </strong>In the current study, it was shown that ART can ameliorate thyroid function, mitigate depression and anxiety symptoms, attenuate cognition impairments, improve liver, kidney and heart functions, and inhibit oxidative stress; however, the effects exerted by ART could not be observed when L1 was silenced by L1 siRNA.</p><p><strong>Conclusion: </strong>These results indicated that ART can upregulate the L1 cell adhesion molecule to ameliorate thyroid function and the complications in adult male hypothyroid rats, laying the foundation for ART to be a novel strategy for the treatment of hypothyroidism.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"17 1","pages":"19"},"PeriodicalIF":1.9,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11331813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Activating transcription factor 3 mediates apoptosis and cell cycle arrest in TP53-mutated anaplastic thyroid cancer cells. 激活转录因子 3 在 TP53 突变的无性甲状腺癌细胞中介导细胞凋亡和细胞周期停滞。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-01 DOI: 10.1186/s13044-024-00202-x
Abolfazl Kooti, Haniyeh Abuei, Alireza Jaafari, Shayan Taki, Jamileh Saberzadeh, Ali Farhadi

Background: It is believed that loss of p53 function plays a crucial role in the progression of well to poorly differentiated thyroid cancers including anaplastic thyroid carcinoma (ATC). Given the poor prognosis of ATC due to its strong therapeutic resistance, there is a need to establish new therapeutic targets to extend the survival of ATC patients. Activating transcription factor 3 (ATF3) can inhibit the oncogenic activity of mutant p53 and, as a result, contribute to tumor suppression in several TP53-mutated cancers. Herein, we demonstrate that the ectopic overexpression of ATF3 leads to the suppression of oncogenic mutant p53 activity in chemo-resistant 8305 C thyroid cancer cells harboring R273C p53 gene mutation.

Methods: The biological behavior of 8305 C cells was assessed pre- and post-transfection with pCMV6-ATF3 plasmid using MTT assay, fluorescent microscopy, cell cycle, and annexin V/PI flow cytometric analysis. The effect of ectopic ATF3 overexpression on the cellular level of p53 was examined by western blotting assay. The mRNA expression levels of TP53, TAp63, ΔNp63, and SHARP1 were evaluated in ectopic ATF3-expressing cells compared to controls.

Results: The overexpression of ATF3 in 8305 C thyroid cancer cells significantly decreased cell viability and induced apoptosis and cell cycle arrest in vitro. The immunoblotting of p53 protein revealed that ATF3 overexpression significantly increased the level of mutant p53 in 8305C cells compared to mock-transfected control cells. Additionally, elevated mRNA levels of TAp63 and SHARP1 and a decreased mRNA level of ΔNp63 were observed in PCMV6-AC-ATF3-transfected 8305 C cells with significant differences compared to the mock and untreated cells.

Conclusion: In light of our findings, it is evident that therapeutic strategies aimed at increasing ATF3 expression or enhancing the interaction between ATF3 and mutant p53 can be a promising approach for the treatment of p53-mutated metastatic thyroid cancer.

背景:人们认为,p53功能的丧失在甲状腺癌(包括甲状腺无节细胞癌(ATC))从分化良好到分化不良的过程中起着至关重要的作用。由于甲状腺癌具有很强的抗药性,预后较差,因此有必要确立新的治疗靶点,以延长甲状腺癌患者的生存期。活化转录因子 3(ATF3)可抑制突变 p53 的致癌活性,从而在多种 TP53 突变癌症中起到抑制肿瘤的作用。在此,我们证明了在携带 R273C p53 基因突变的耐化疗 8305 C 甲状腺癌细胞中,ATF3 的异位过表达可抑制突变体 p53 的致癌活性:使用 MTT 试验、荧光显微镜、细胞周期和附件素 V/PI 流式细胞分析评估了转染 pCMV6-ATF3 质粒前后 8305 C 细胞的生物学行为。通过 Western 印迹检测了异位 ATF3 过表达对细胞中 p53 水平的影响。与对照组相比,评估了异位表达ATF3的细胞中TP53、TAp63、ΔNp63和SHARP1的mRNA表达水平:结果:ATF3在8305 C甲状腺癌细胞中的过表达显著降低了细胞活力,并诱导体外细胞凋亡和细胞周期停滞。p53蛋白的免疫印迹显示,与模拟转染的对照细胞相比,ATF3的过表达明显增加了8305C细胞中突变p53的水平。此外,在 PCMV6-AC-ATF3 转染的 8305 C 细胞中观察到 TAp63 和 SHARP1 的 mRNA 水平升高,ΔNp63 的 mRNA 水平降低,与模拟和未处理的细胞相比差异显著:根据我们的研究结果,旨在增加 ATF3 表达或增强 ATF3 与突变 p53 之间相互作用的治疗策略显然是治疗 p53 突变转移性甲状腺癌的一种很有前景的方法。
{"title":"Activating transcription factor 3 mediates apoptosis and cell cycle arrest in TP53-mutated anaplastic thyroid cancer cells.","authors":"Abolfazl Kooti, Haniyeh Abuei, Alireza Jaafari, Shayan Taki, Jamileh Saberzadeh, Ali Farhadi","doi":"10.1186/s13044-024-00202-x","DOIUrl":"10.1186/s13044-024-00202-x","url":null,"abstract":"<p><strong>Background: </strong>It is believed that loss of p53 function plays a crucial role in the progression of well to poorly differentiated thyroid cancers including anaplastic thyroid carcinoma (ATC). Given the poor prognosis of ATC due to its strong therapeutic resistance, there is a need to establish new therapeutic targets to extend the survival of ATC patients. Activating transcription factor 3 (ATF3) can inhibit the oncogenic activity of mutant p53 and, as a result, contribute to tumor suppression in several TP53-mutated cancers. Herein, we demonstrate that the ectopic overexpression of ATF3 leads to the suppression of oncogenic mutant p53 activity in chemo-resistant 8305 C thyroid cancer cells harboring R273C p53 gene mutation.</p><p><strong>Methods: </strong>The biological behavior of 8305 C cells was assessed pre- and post-transfection with pCMV6-ATF3 plasmid using MTT assay, fluorescent microscopy, cell cycle, and annexin V/PI flow cytometric analysis. The effect of ectopic ATF3 overexpression on the cellular level of p53 was examined by western blotting assay. The mRNA expression levels of TP53, TAp63, ΔNp63, and SHARP1 were evaluated in ectopic ATF3-expressing cells compared to controls.</p><p><strong>Results: </strong>The overexpression of ATF3 in 8305 C thyroid cancer cells significantly decreased cell viability and induced apoptosis and cell cycle arrest in vitro. The immunoblotting of p53 protein revealed that ATF3 overexpression significantly increased the level of mutant p53 in 8305C cells compared to mock-transfected control cells. Additionally, elevated mRNA levels of TAp63 and SHARP1 and a decreased mRNA level of ΔNp63 were observed in PCMV6-AC-ATF3-transfected 8305 C cells with significant differences compared to the mock and untreated cells.</p><p><strong>Conclusion: </strong>In light of our findings, it is evident that therapeutic strategies aimed at increasing ATF3 expression or enhancing the interaction between ATF3 and mutant p53 can be a promising approach for the treatment of p53-mutated metastatic thyroid cancer.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"17 1","pages":"12"},"PeriodicalIF":1.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interrelationship between thyroid hormones and reduced renal function, a review article. 甲状腺激素与肾功能减退之间的相互关系,综述文章。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-15 DOI: 10.1186/s13044-024-00201-y
Sadaf Agahi, Atieh Amouzegar, Mohammadjavad Honarvar, Fereidoun Azizi, Ladan Mehran

Background: Understanding the relationship of thyroid hormones with the development of chronic kidney disease (CKD) has important clinical implications for managing patients with both thyroid and kidney dysfunction. In this review, our purpose was to provide a thorough comprehension of the interplay between thyroid hormones, thyroid dysfunctions, and CKD. While there is evidence linking thyroid hormone levels to renal diseases, the association between thyroid hormones, specifically within the normal range, and the risk of CKD incidence is still a subject of debate. The Google Scholar, PubMed, Scopus, and Web of Science, were searched using the medical subject heading (MeSH) terms for the relevant keywords up to December 2023.

Conclusion: Based on the review, the development of CKD is more consistently associated with higher serum TSH and thereafter lower serum free T3 levels; however, its association with free T4 is more controversial. Furthermore, subclinical and overt hypothyroidisms were considerably associated with incident CKD. Hyperthyroidism and Hashimoto thyroiditis might increase the risk of CKD.

背景:了解甲状腺激素与慢性肾脏病(CKD)发病的关系对于管理同时患有甲状腺和肾功能异常的患者具有重要的临床意义。在这篇综述中,我们的目的是全面了解甲状腺激素、甲状腺功能障碍和慢性肾脏病之间的相互作用。尽管有证据表明甲状腺激素水平与肾脏疾病有关,但甲状腺激素(尤其是正常范围内的甲状腺激素)与慢性肾功能衰竭发病风险之间的关系仍存在争议。我们使用医学主题词表(MeSH)对谷歌学术、PubMed、Scopus 和 Web of Science 进行了检索,相关关键词的检索期截至 2023 年 12 月:根据综述,慢性肾功能衰竭的发生与血清促甲状腺激素(TSH)升高和血清游离 T3 水平降低的关系较为一致;但与游离 T4 的关系却存在较大争议。此外,亚临床和显性甲状腺功能减退症与慢性肾功能衰竭的发生有很大关系。甲状腺功能亢进症和桥本氏甲状腺炎可能会增加罹患慢性肾脏病的风险。
{"title":"Interrelationship between thyroid hormones and reduced renal function, a review article.","authors":"Sadaf Agahi, Atieh Amouzegar, Mohammadjavad Honarvar, Fereidoun Azizi, Ladan Mehran","doi":"10.1186/s13044-024-00201-y","DOIUrl":"10.1186/s13044-024-00201-y","url":null,"abstract":"<p><strong>Background: </strong>Understanding the relationship of thyroid hormones with the development of chronic kidney disease (CKD) has important clinical implications for managing patients with both thyroid and kidney dysfunction. In this review, our purpose was to provide a thorough comprehension of the interplay between thyroid hormones, thyroid dysfunctions, and CKD. While there is evidence linking thyroid hormone levels to renal diseases, the association between thyroid hormones, specifically within the normal range, and the risk of CKD incidence is still a subject of debate. The Google Scholar, PubMed, Scopus, and Web of Science, were searched using the medical subject heading (MeSH) terms for the relevant keywords up to December 2023.</p><p><strong>Conclusion: </strong>Based on the review, the development of CKD is more consistently associated with higher serum TSH and thereafter lower serum free T3 levels; however, its association with free T4 is more controversial. Furthermore, subclinical and overt hypothyroidisms were considerably associated with incident CKD. Hyperthyroidism and Hashimoto thyroiditis might increase the risk of CKD.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"17 1","pages":"14"},"PeriodicalIF":1.9,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypothyroidism after hemithyroidectomy: a systematic review and meta-analysis. 甲状腺半切除术后甲状腺功能减退:系统回顾和荟萃分析。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-08 DOI: 10.1186/s13044-024-00200-z
Dominic Cooper, Rajneesh Kaur, Femi E Ayeni, Guy D Eslick, Senarath Edirimanne

Background: The incidence of hypothyroidism following hemithyroidectomy and risk factors associated with its occurrence are not completely understood. This systematic review investigated the incidence and risk factors for hypothyroidism, thyroxine supplementation following hemithyroidectomy as well as the course of post-operative hypothyroidism, including the time to hypothyroidism and incidence of transient hypothyroidism.

Methods: Searches were conducted in MEDLINE, EMBASE, Scopus, and Cochrane library for studies reporting the incidence of hypothyroidism or thyroxine supplementation following hemithyroidectomy.

Results: Sixty-six studies were eligible for inclusion: 36 reported risk factors, and 27 reported post-operative course of hypothyroidism. Median follow-up was 25.2 months. The pooled incidence of hypothyroidism was 29% (95% CI, 25-34%; P<0.001). Transient hypothyroidism occurred in 34% of patients (95% CI, 21-47%; P<0.001). The pooled incidence of thyroxine supplementation was 23% (95% CI, 19-27%; P<0.001), overt hypothyroidism 4% (95% CI, 2-6%, P<0.001). Risk factors for development of hypothyroidism included pre-operative thyroid stimulating hormone (TSH) (WMD, 0.87; 95% CI, 0.75-0.98; P<0.001), TSH ≥ 2 mIU/L (RR, 2.87; 95% CI, 2.43-3.40; P<0.001), female sex (RR, 1.19; 95% CI, 1.08-1.32; P=0.007), age (WMD, 2.29; 95% CI, 1.20-3.38; P<0.001), right sided hemithyroidectomy (RR, 1.35; 95% CI, 1.10-1.65, P=0.003), the presence of autoantibodies anti-TPO (RR, 1.92; 95% CI, 1.49-2.48; P<0.001), anti-Tg (RR, 1.53; 95% CI, 1.40-1.88; P<0.001), and Hashimoto's thyroiditis (RR, 2.05; 95% CI, 1.57-2.68; P=0.001).

Conclusion: A significant number of patients will develop hypothyroidism or require thyroxine following hemithyroidectomy. An awareness of patient risk factors and postoperative thyroid function course will assist in counselling patients on their risk profile and guiding management.

背景:甲状腺半切除术后甲状腺功能减退症的发病率及其相关风险因素尚未完全明了。本系统综述调查了甲状腺功能减退症的发生率和风险因素、甲状腺半切术后甲状腺素的补充以及术后甲状腺功能减退症的病程,包括甲状腺功能减退症的发生时间和一过性甲状腺功能减退症的发生率:方法:在MEDLINE、EMBASE、Scopus和Cochrane图书馆中检索报告甲状腺半切术后甲减或补充甲状腺素发生率的研究:结果:66项研究符合纳入条件:36项报告了风险因素,27项报告了甲状腺功能减退症的术后病程。中位随访时间为 25.2 个月。汇总的甲状腺功能减退症发病率为 29%(95% CI,25%-34%;PC 结论:半甲状腺切除术后,很多患者会出现甲状腺功能减退或需要使用甲状腺素。了解患者的风险因素和术后甲状腺功能情况将有助于向患者提供有关其风险情况的咨询并指导治疗。
{"title":"Hypothyroidism after hemithyroidectomy: a systematic review and meta-analysis.","authors":"Dominic Cooper, Rajneesh Kaur, Femi E Ayeni, Guy D Eslick, Senarath Edirimanne","doi":"10.1186/s13044-024-00200-z","DOIUrl":"10.1186/s13044-024-00200-z","url":null,"abstract":"<p><strong>Background: </strong>The incidence of hypothyroidism following hemithyroidectomy and risk factors associated with its occurrence are not completely understood. This systematic review investigated the incidence and risk factors for hypothyroidism, thyroxine supplementation following hemithyroidectomy as well as the course of post-operative hypothyroidism, including the time to hypothyroidism and incidence of transient hypothyroidism.</p><p><strong>Methods: </strong>Searches were conducted in MEDLINE, EMBASE, Scopus, and Cochrane library for studies reporting the incidence of hypothyroidism or thyroxine supplementation following hemithyroidectomy.</p><p><strong>Results: </strong>Sixty-six studies were eligible for inclusion: 36 reported risk factors, and 27 reported post-operative course of hypothyroidism. Median follow-up was 25.2 months. The pooled incidence of hypothyroidism was 29% (95% CI, 25-34%; P<0.001). Transient hypothyroidism occurred in 34% of patients (95% CI, 21-47%; P<0.001). The pooled incidence of thyroxine supplementation was 23% (95% CI, 19-27%; P<0.001), overt hypothyroidism 4% (95% CI, 2-6%, P<0.001). Risk factors for development of hypothyroidism included pre-operative thyroid stimulating hormone (TSH) (WMD, 0.87; 95% CI, 0.75-0.98; P<0.001), TSH ≥ 2 mIU/L (RR, 2.87; 95% CI, 2.43-3.40; P<0.001), female sex (RR, 1.19; 95% CI, 1.08-1.32; P=0.007), age (WMD, 2.29; 95% CI, 1.20-3.38; P<0.001), right sided hemithyroidectomy (RR, 1.35; 95% CI, 1.10-1.65, P=0.003), the presence of autoantibodies anti-TPO (RR, 1.92; 95% CI, 1.49-2.48; P<0.001), anti-Tg (RR, 1.53; 95% CI, 1.40-1.88; P<0.001), and Hashimoto's thyroiditis (RR, 2.05; 95% CI, 1.57-2.68; P=0.001).</p><p><strong>Conclusion: </strong>A significant number of patients will develop hypothyroidism or require thyroxine following hemithyroidectomy. An awareness of patient risk factors and postoperative thyroid function course will assist in counselling patients on their risk profile and guiding management.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"17 1","pages":"18"},"PeriodicalIF":1.9,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Thyroid Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1